A Study to Determine the Effects of MK0557 in Obese Subjects (0557-006)(COMPLETED)

This study has been completed.
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
First received: September 19, 2007
Last updated: August 11, 2015
Last verified: August 2015
The purpose of this study is to assess the effects of MK0557 on body weight in obese subjects.

Condition Intervention Phase
Drug: MK0557
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment

Further study details as provided by Merck Sharp & Dohme Corp.:

Study Start Date: September 2002
Study Completion Date: June 2003
Primary Completion Date: June 2003 (Final data collection date for primary outcome measure)

Ages Eligible for Study:   21 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women between 21 and 65 years of age, willing to avoid all prescription and nonprescription medicine to alter body weight for entire study

Exclusion Criteria:

  • You are or plan to become pregnant
  • You have smoked or used nicotine within 6 months of the study
  • History of abusing alcohol and/or drugs
  • History of a stroke, you have diabetes mellitus, you are taking medication for high blood pressure, you have had recent surgery, you have been involved in another study within 3 months of study, use of cholesterol or anti-seizure medication during the study
  • Have participated in a weight loss program 3 months before the study or during the course of the study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00533598

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.
  More Information

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00533598     History of Changes
Other Study ID Numbers: 0557-006  2007_613 
Study First Received: September 19, 2007
Last Updated: August 11, 2015
Health Authority: United States: Food and Drug Administration

ClinicalTrials.gov processed this record on May 22, 2016